We are pleased to announce that icometrix is now a GE HealthCare company. Click here to learn more.
.png)
Join us for these sessions
Abstracts*
xx
xx
xx
POSTER SESSION
xx
Learn more about icobrain aria**
icobrain aria can be used to assess side effects to amyloid-targeting therapies for Alzheimer's disease, known as amyloid-related imaging abnormalities (ARIA). It can help improve clinical confidence when elevating the presence of parenchymal vasogenic edema, gyral swelling and sulcal effusion.
Disease-specific solutions supporting clinical decisions
%20(1).png)
.png)
%20(1).png)
%20(1).png)
%20(1).png)
%20(1).png)
%20(1).png)
Latest news
MSAA and icometrix Partner to Expand MRI Access and Equity in MS Care
15 June 2026 at 7:42:28 pm
A New Era in Alzheimer’s Disease Care: Transforming Neurology with AI
10 June 2026 at 5:03:34 pm
Multiple sclerosis: the EU turns to artificial intelligence for increasingly predictive and personalised therapies
9 December 2025 at 8:11:03 pm
Get reimbursement assistance at RSNA
More than 30 U.S. insurers have successfully processed claims for CPT III® codes 0865T & 0866T for icobrain analyses.
Our reimbursement team is here to guide you every step of the way with billing and coding guides, medical necessity templates, prior authorization checklists, and appeal support.
Book your meeting during RSNA and indicate that you’re interested in reimbursement support - our team will be ready to discuss your specific case and provide tailored resources.
Key scientific publications
* Ongoing research with findings subject to change.
**icobrain aria is 510(k) cleared. CE marked as part of icobrain mr. Not available in all markets.
JB38446xx